DNLI - デナリ・セラピュ―ティクス (Denali Therapeutics Inc.) デナリ・セラピュ―ティクス

 DNLIのチャート


 DNLIの企業情報

symbol DNLI
会社名 Denali Therapeutics Inc (デナリ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 デナリ・セラピューティクス(Denali Therapeutics Inc.)はバイオテクノロジー企業である。同社は、アルツハイマー病、パーキンソン病、筋萎縮性側索硬化症(ALS)などの神経変性疾患患者の治療法の発見と開発に従事する。同社は、遺伝的原因及び神経変性疾患の根底にある生物学的プロセスに関する科学的な洞察に基づいて、治療薬の多様なポートフォリオを開発する。同社は、脱遺伝子遺伝子(変異した場合に神経変性疾患を引き起こす遺伝子)、欠陥細胞内輸送、グリア機能障害および軸索変性を含む、神経変性のトリガーまたはエフェクターとして関与する約4つの特異的経路を選択した。同社の開発プログラムには、リソソーム機能経路、グリア細胞生物学的経路、および細胞恒常性経路が含まれる。同社の製品パイプラインには、DNL201、DNL 151、ATV:aSyn、ETV:IDS、DNL747、ATV:TREM2などの薬物候補が含まれる。   デナリ・セラピュ―ティクスは米国のバイオ医薬品会社。アルツハイマ―病、パ―キンソン病、筋萎縮性側索硬化症(ALS)などに代表される神経変性疾患に対する治療薬の発見・開発に従事。疾患の原因やリスク要因に直接対処することを目指し、6つの異なるプログラムで臨床開発及び臨床前開発に取り組む。本社はカリフォルニア州サウス・サンフランシスコ。   Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
本社所在地 151 Oyster Point Blvd. 2nd Floor South San Francisco CA 94080 USA
代表者氏名 Marc Tessier-Lavignec マルクテッシーエ - ラヴィーニェック
代表者役職名 Chairman of the Board Co-Founder
電話番号 +1 650-866-8548
設立年月日 41548
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 130人
url www.denalitherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/dnli
adr_tso
EBITDA EBITDA(百万ドル) -124.66400
終値(lastsale) 18.34
時価総額(marketcap) 1738762415.74
時価総額 時価総額(百万ドル) 1690.411
売上高 売上高(百万ドル) 2.28900
企業価値(EV) 企業価値(EV)(百万ドル) 1317.82
当期純利益 当期純利益(百万ドル) -123.13300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Denali Therapeutics Inc revenues increased from $0K to $2.3M. Net loss increased 80% to $78.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development Expense - Balanci increase of 89% to $68.7M (expense) Stock-based Compensation in R&D increase from $1.2M to $4.3M (expense) Selling.

 DNLIのテクニカル分析


 DNLIのニュース

   Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi  2020/06/09 20:30:00 GlobeNewswire
Denali and Sanofi pause DNL747(a) clinical activities based on the totality of DNL747 data and a superior profile of backup compound DNL788(b)Denali and…
   What Makes Denali Therapeutics Inc. (DNLI) a New Buy Stock  2020/05/21 16:00:14 Zacks Investment Research
Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
   Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update  2020/05/07 20:30:00 GlobeNewswire
SOUTH SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio…
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   Has Denali Therapeutics (DNLI) Outpaced Other Medical Stocks This Year?  2020/02/07 16:30:10 Zacks Investment Research
Is (DNLI) Outperforming Other Medical Stocks This Year?
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   Has Denali Therapeutics (DNLI) Outpaced Other Medical Stocks This Year?  2020/02/07 16:30:10 Zacks Investment Research
Is (DNLI) Outperforming Other Medical Stocks This Year?
   Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 35%  2020/01/30 15:54:29 Nasdaq
Once again, the world is gripped by uncertainty. Fear of an international outbreak of coronavirus, on top of recent worrisome developments between the US and Iran, have spooked investors, sending all three major indexes down over the last week. However, no matter the global outlook, one thing remains certain; investors are still in the game, on the lookout for the best opportunities the market presents. As it happens, if you know where to look, a world teetering precariously on the edge often presents specific investment opportunities. With this in mind, we pulled up two of Goldman Sachs’ recent stock picks which the renowned investment bank thinks can soar in the coming months. Using TipRanks’ Stock Comparison tool, we were able to read the fine print on what 2020 has in store for the two tickers. Let’s take a closer look. Denali Therapeutics Inc. ( DNLI ) Denali Therapeutics has started off 2020 with a bang. The neurodegenerative disease-focused biotech is up by 34 % year-to-date. The reason for the surge?
   Denali Therapeutics down 3% premarket on pricing equity offering  2020/01/29 10:07:02 Seeking Alpha
Denali Therapeutics (NASDAQ:DNLI) has priced its public offering of 7,826,087 common shares at $23/share, for expected gross proceeds of $180M. Greenshoe o
   The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics  2020/01/28 12:12:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN )(announced early termination of waiting period for its proposed acquisition by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN )) Cidara Therapeutics Inc (NASDAQ: CDTX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )(saw a coronavirus-induced rally ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY )(reacted to its Q3 results) Inovio Pharmaceuticals Inc (NASDAQ: INO )(announced Nevro Corp (NYSE: NVRO ) Oyster Point Pharma Inc (NASDAQ: OYST ) Quest Diagnostics Inc (NYSE: DGX ) Rapt Therapeutics Inc (NASDAQ: RAPT ) SI-Bone Inc (NASDAQ: SIBN ) Vaccinex Inc (NASDAQ: VCNX ) Vir Biotechnology Inc (NASDAQ: VIR ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. 27) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Avanos Medical Inc (NYSE: AVNS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Correvio Pharma Corp (NASDAQ: CORV ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Heat Biologics Inc (NASDAQ: HTBX ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kura Oncology Inc (NASDAQ: KURA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) MediciNova, Inc.
   3 Gene Therapy Stocks For A Biotech Portfolio  2019-05-20
Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 デナリ・セラピュ―ティクス DNLI Denali Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)